Bioclinic Naturals are excited to announce a ground-breaking 5-year research collaboration with Macquarie University, which will build on the Scobiotic™ novel IP, pertaining to host and microbiome interactions.
The research partnership will focus on restoration of normal microbiomes in gut issues such as IBS, examining and utilising the synergistic effects of the host, the host microbiome and Scobiotics™ (revolutionary, syntrophic mixed cultures of living organisms, prebiotics and substrates) by identifying the best combinations to achieve homeostasis.
Macquarie University’s new ARC Training Centre for Facilitated Advancement of Australia’s Bioactives (FAAB) will bring together industry leading Bioclinic Naturals with Macquarie University, Deakin University, the University of SA and Western Sydney University with research universities in the UK, Germany and Brazil to research products of high molecular complexity that can relieve chronic and acute health problems. The research with Bioclinic Naturals is a pillar project for the facility.
FAAB’s leadership team consist of training centre Director Professor Alison Rodger – who was recently made a Fellow of the Australian Academy of Science, Partnerships Director Professor Anwar Sunna and Research Director Dr Alfonso Garcia-Bennett.
Partnerships Director for the Facilitated Advancement of Australia’s Bioactives (FAAB), Professor Anwar Sunna says of the partnership: “We are excited to be entering into this partnership with Bioclinic Naturals, to apply advanced analytical methods to determine modes of action for bioactives with potential lifestyle and nutritional benefits. This partnership will provide support for training the next generation of industry-embedded experts and creation of new high-skilled jobs for FAAB graduates.”
The research will also explore:
• Interactions between the body, symbiotic organisms, chemical precursors and short chain fatty acids.
• Optimising best combinations with regards to host interaction and metabolite production.
• Metabolomics for established and novel compounds.
• Proteomics investigations, examining nucleotide sequences as a basis for selection for specific interactions and effects, such as bacterial surface level interactions.
• Ensuring the best viability of the combination ingredients in new product ranges.
• Elucidating and validating new synergistic processes within the microbiome.
Evan Hayes, Managing Director of Factors Group ANZ (parent company of Bioclinic Naturals), says of the collaboration “Microbiota-based bioactives consisting of probiotics and yeasts can play an important role in the restoration of ‘normal’ microbiomes and gastrointestinal functions. This ground-breaking partnership will focus on uncovering how endogenous chemicals promoted by our Scobiotic™ formulas function as microbiota precursors and substrates, having a role in GIT wellness in areas such as energy production, inflammation reduction and pathogen elimination.”
“The synergistic effects will be assessed with cutting edge microbiome analysis to identify underlying imbalances that are associated with gastrointestinal disturbances. The ongoing research represents a paradigm shift in examining how the relationship between microbial and single cell organisms work in harmony and in parallel with the gut, and how those interactions can be manipulated for diverse beneficial effects. Macquarie University are world-leaders in biotechnology research, and we are delighted to be a part of the FAAB initiative. I believe this collaboration will change the way we look at probiotics.”
Bioclinic Naturals are committed to investing in progressive research that furthers scientific understanding and provides opportunities for continued innovation in personalised medicine for practitioners, spanning existing and emerging conditions.